Genetic diseases caused by nonsense mutations—where a single DNA change creates a premature stop signal—affect millions worldwide, cutting short protein production and causing conditions from cystic fibrosis to muscular dystrophy. Traditional approaches have struggled to restore meaningful protein function across the diverse landscape of these mutations. Transfer RNA editing emerges as a transformative strategy that could fundamentally reshape treatment possibilities for this broad class of inherited disorders. The approach involves precisely modifying transfer RNA molecules, the cellular machinery that translates genetic instructions into proteins, enabling them to read through premature stop signals and continue protein synthesis. Unlike previous readthrough therapies that worked inconsistently across different mutation types, tRNA editing offers the potential for mutation-specific interventions tailored to individual genetic defects. Early research demonstrates that engineered tRNA molecules can successfully bypass nonsense mutations in laboratory models, restoring substantial protein function without disrupting normal cellular processes. This precision represents a significant advance over small-molecule readthrough drugs, which often produced variable results and off-target effects. The therapeutic implications extend far beyond rare genetic diseases, as nonsense mutations account for roughly 11% of all disease-causing genetic variants. However, key challenges remain, including efficient delivery of edited tRNA to relevant tissues, ensuring long-term safety profiles, and scaling manufacturing for diverse mutation-specific therapies. The approach also raises questions about optimal timing of intervention and whether early treatment could prevent irreversible tissue damage in progressive genetic conditions. While still in early development, tRNA editing represents a paradigm shift toward precision genetic medicine that addresses root molecular causes rather than managing downstream symptoms.